SAN FRANCISCO - "Fast" seemed the watchword for Takeda Pharmaceutical Co. Ltd. this week, as it officially closed its $62 billion acquisition of rare disease specialist Shire plc. "We don't want to lose momentum in the business," Takeda President CEO Christophe Weber said during a Tuesday presentation at the J.P. Morgan Healthcare Conference. "We want to integrate the two companies very quickly and to really gain the full benefit of the combination as soon as possible," he said.